脑血疏口服液联合丁苯酞治疗急性脑梗死的临床研究

目的探讨脑血疏口服液联合丁苯酞治疗急性脑梗死的临床疗效。方法收集2015年1月—2016年1月陕西省人民医院神经脑科病院收治的86例急性脑梗死患者,随机分为对照组(43例)和治疗组(43例)。两组患者均按急性脑梗死诊疗指南给予常规治疗。对照组静脉滴注丁苯酞氯化钠注射液,25 mg/次,2次/d。治疗组在对照组的基础上口服脑血疏口服液,10 m L/次,3次/d。两组患者均连续治疗14 d。观察两组的临床疗效,比较两组治疗前后NHISS评分、Barthel指数、血清学指标。结果治疗后,对照组与治疗组治疗的总有效率分别为81.40%和95.35%,两组总有效率比较差异具有统计学意义(P0.05)。治疗后,两组患者NIHSS评分明显降低,Barthel指数明显升高,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组NIHSS评分和Barthel指数改善程度优于对照组(P0.05)。治疗后两组患者血清超敏C-反应蛋白(hs-CRP)、基质金属蛋白酶-9(MMP-9)水平较治疗前明显降低,一氧化氮(NO)、血管内皮生长因子(VEGF)、脑源性神经营养因子(BDNF)和碱性成纤维细胞生长因子(b FGF)水平均较治疗前明显增加,同组治疗前后比较差异具有统计学意义(P0.05);且治疗组上述血清学指标改善程度优于对照组,两组比较差异具有统计学意义(P0.05)。结论脑血疏口服液联合丁苯酞治疗急性脑梗死可提高患者临床疗效,改善血液流变学状态,降低血清炎性因子水平,具有一定的临床推广应用价值。

Clinical study on Naoxueshu Oral Liquid combined with butylphthalide in treatment of acute cerebral infarction

Objective To explore the clinical efficacies of Naoxueshu Oral Liquid combined with butylphthalide in treatment of acute cerebral infarction. Methods Patients (86 cases) with acute cerebral infarction in Shaanxi Provincial People''s Hospital from January 2015 to January 2016 were randomly divided into control (43 cases) and treatment groups (43 cases). All patients in two groups were treated with the conditional therapy according to the guidelines for diagnosis and treatment of acute cerebral infarction. Patients in the control group were iv administered with Butylphthalide and Sodium Chloride Injection, 25 mg/time, twice daily. Patients in the treatment group were po administered with Naoxueshu Oral Liquid on the basis of the control group, 10 mL/time, three times daily. The patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and NIHSS score, Barthel index, and serological indexes before and after treatment in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.40% and 95.35%, respectively, and there were differences between two groups (P<0.05). After treatment, NIHSS scores were obviously decreased, but Barthel indexes were increased, and the differences were statistically significant in the same group (P<0.05); The improvement of NIHSS scores and Barthel indexes in the treatment group were better than those in the control group (P<0.05). After treatment, hs-CRP and MMP-9 levels were significantly decreased, NO, VEGF, BDNF, and bFGF levels were significantly increased, and the differences were statistically significant in the same group (P<0.05); The serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Naoxueshu Oral Liquid combined with Butylphthalide in treatment of acute cerebral infarction can improve the clinical efficacy, hemorheological indexes, and reduce the levels of serum inflammatory factors, which has a certain clinical application value.